Sareum Holdings Secures US Patent for Autoimmune Drug

Clinical-stage biotechnology company Sareum Holdings announced on Monday that it has received a notice of allowance from the US Patent and Trademark Office (USPTO) for its patent on SDC-1801, a dual TYK2/JAK1 kinase inhibitor. The AIM-listed company is developing SDC-1801 as a potential treatment for various autoimmune diseases.

The US patent will offer substantial protection for the chemical structure of SDC-1801 and its analogues, as well as their application in treating inflammatory diseases and specific methods of chemical synthesis. This latest patent approval follows similar protections granted by the European Patent Office, China National Intellectual Property Administration, and Japan Patent Office, ensuring Sareum’s intellectual property is secured across key global markets.

Sareum anticipates that the US patent will be officially granted by the end of 2024, subject to the completion of standard formalities with the USPTO.

“We are pleased to extend the patent protection for SDC-1801, particularly following the promising data from our phase 1a trial, which suggests our inhibitor may offer significant benefits over other TYK2/JAK1 kinase inhibitors,” said Dr. John Reader, Sareum’s chief scientific officer. “We remain committed to advancing SDC-1801 through clinical development, aiming to create new treatments for autoimmune diseases and cancers.”